APMD Stock Forecast: Apnimed, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 8 Aug 2026 — in the weakest quartile.
APMD stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Apnimed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (44): Smaller than most of the companies we track.
Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Apnimed, Inc. — and when they’d sell — is the membership.
APMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on APMD, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
APMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Apnimed, Inc. (APMD) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 9.1×
- Price / sales
- 8.9×
- Price / book
- 3.1×
- EV / EBITDA
- 9.4×
Cheaper than 60% of US stocks
Cheaper than 16% of US stocks
Cheaper than 34% of US stocks
Cheaper than 41% of US stocks
- Revenue growth (YoY)
- 2608.8%
- Earnings growth (YoY)
- —
- Gross margin
- 97.5%
- Operating margin
- 80.2%
- Net margin
- −26.5%
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 14% of US stocks
- Return on equity
- 0.3%
- Return on assets
- −1.3%
- Dividend yield
- —
Higher than 44% of US stocks
Higher than 39% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
APMD vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APMD appears on the weeks it earns a place.
Frequently asked questions about APMD stock
How does Ticker Nerd's model rank APMD?
As at 8 Aug 2026, Apnimed, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (44 of 100).
What is the APMD stock forecast for 2030?
No analyst covering Apnimed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APMD are extrapolating price history, which says nothing about the business.
What does Apnimed, Inc. do?
Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on developing and commercializing novel oral therapies for sleep-related breathing diseases.
About Apnimed, Inc.
Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on developing and commercializing novel oral therapies for sleep-related breathing diseases. Its core specialization is obstructive sleep apnea, where it aims to address the underlying neuromuscular dysfunction that contributes to airway collapse during sleep. Apnimed’s lead product candidate, AD109, also known as Oxnimbi, is an investigational, fixed-dose oral combination therapy designed as a once-daily, at-bedtime pill to improve upper airway muscle activity and oxygenation in adults with mild to severe obstructive sleep apnea. The company is advancing a broader portfolio of oral therapeutic candidates for sleep-related breathing disorders, positioning itself within the healthcare and biotechnology sectors at the intersection of drug discovery, clinical development, and sleep medicine. Apnimed primarily serves physicians, sleep centers, and healthcare systems seeking pharmacologic alternatives to device-based treatments, with an emphasis on convenient, non-invasive options. Founded in 2017 and headquartered in Cambridge, Massachusetts, Apnimed operates today as a specialized player in neurobiology-driven therapies for sleep-related breathing conditions.
CEO Mr. Kevin Robert Lind · 65 employees · United States · https://apnimed.com